We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Agencourt Bioscience Enters Into Supply Agreement with Affymetrix

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Agencourt Bioscience Corporation, a wholly owned subsidiary of Beckman Coulter has announced the signing of a distribution and supply agreement with Affymetrix Inc.

Agencourt will provide a nucleic acid purification product, Agencourt RNAClean, to be included in the reagent kit for Affymetrix' GeneChip® Array Station.

Agencourt RNAClean is designed to provide a reproducible method for preparing quality nucleic acids for use in applications such as microarray analysis.

Agencourt RNAClean enables the researcher to use one product to complete both cDNA and cRNA purification steps.

Affymetrix will incorporate the SPRI magnetic bead technology into the automated GeneChip Array Station reagent product offering.

"We are pleased that Affymetrix has selected our product for cDNA and cRNA cleanup in support of their GeneChip Array Station," stated Lynn Doucette- Stamm, Ph.D., Agencourt's vice president business development.

"Beta site testing of this product for use with systems installed by Affymetrix has been outstanding, and we look forward to continued growth of the product line."

"The integration of the SPRI technology and specifically the Agencourt RNAClean product allows us to provide our customers with an optimal automated target preparation solution for their GeneChip microarray experiments," said Alan Dance, senior vice president of business development at Affymetrix.

"By improving data consistency and decreasing the hands-on time needed to perform experiments, the Affymetrix Array Station enables scientists to accelerate discovery, publication, and bring new tests and therapies to market more quickly."